Share on StockTwits

Stock analysts at Jefferies Group decreased their price target on shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) from $17.00 to $16.00 in a report issued on Tuesday. The firm currently has a “buy” rating on the stock. Jefferies Group’s price target indicates a potential upside of 111.64% from the stock’s previous close.

Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 2.65% during mid-day trading on Tuesday, hitting $7.36. The stock had a trading volume of 12,996 shares. Aquinox Pharmaceuticals has a 52 week low of $7.32 and a 52 week high of $14.35. The stock has a 50-day moving average of $8.36 and a 200-day moving average of $9.75. The company’s market cap is $78.6 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its earnings data on Monday, August 11th. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.27) by $0.24. Analysts expect that Aquinox Pharmaceuticals will post $-1.22 EPS for the current fiscal year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing drug candidates to treat inflammation and cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.